NEJM Interviews
Insightful conversations with leading experts in the field of health care, medical research, policy, and more from the New England Journal of Medicine (NEJM). Each episode examines the many complexities found at the junction of medicine and society.
Latest episodes
Dec 11, 2024 • 9min
NEJM Interview: Bindu Kanapuru on the FDA’s new expedited withdrawal procedure for accelerated approvals.
Bindu Kanapuru is a hematologist–oncologist physician in the Office of Oncologic Diseases at the FDA’s Center for Drug Evaluation and Research. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. B. Kanapuru and Others. Autopsy of a Drug Withdrawal — The Case of Melphalan Flufenamide. N Engl J Med 2024;391:2177-2179.
Dec 4, 2024 • 11min
NEJM Interview: Karen Joynt Maddox on the Transforming Episode Accountability Model recently announced by CMS.
Karen Joynt Maddox is an associate professor of medicine at Washington University School of Medicine. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. S.A. Shashikumar, A.M. Ryan, and K.E. Joynt Maddox. Medicare’s New Mandatory Bundled-Payment Program — Are We Ready for TEAM? N Engl J Med 2024;391:2065-2067.
Nov 27, 2024 • 13min
NEJM Interview: Andrew Hantel on a source of discrimination against some patients in cancer research and care practices.
Andrew Hantel is an assistant professor of medicine at Harvard Medical School and a faculty member in the Divisions of Leukemia and Population Sciences at Dana-Farber Cancer Institute and at the HMS Center for Bioethics. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. A. Hantel and Others. The Duffy Null Phenotype — Addressing a Source of Discrimination in Cancer Care. N Engl J Med 2024;391:1969-1972.
Nov 20, 2024 • 10min
NEJM Interview: Benjamin Rome on the results of the initial round of drug-price negotiation under the Inflation Reduction Act.
Benjamin Rome is a physician and health policy researcher at Brigham and Women’s Hospital and an assistant professor of medicine at Harvard Medical School. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. B.N. Rome, A.S. Kesselheim, and W.B. Feldman. Medicare’s First Round of Drug-Price Negotiation — Measuring Success. N Engl J Med 2024;391:1865-1868.
Nov 17, 2024 • 5min
NEJM at AHA — Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease
Eric Rubin is the Editor-in-Chief of the Journal. Jane Leopold is a Deputy Editor of the Journal. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E.J. Rubin, J. Leopold, and S. Morrissey. NEJM at AHA — Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease. N Engl J Med. DOI: 10.1056/NEJMe2414477.
Nov 16, 2024 • 4min
NEJM at AHA — Routine Spironolactone in Acute Myocardial Infarction
Eric Rubin is the Editor-in-Chief of the Journal. Jane Leopold is a Deputy Editor of the Journal. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E.J. Rubin, J. Leopold, and S. Morrissey. NEJM at AHA — Routine Spironolactone in Acute Myocardial Infarction. N Engl J Med. DOI: 10.1056/NEJMe2414472.
Nov 15, 2024 • 3min
NEJM at AHA — Intensive Blood-Pressure Control in Patients with Type 2 Diabetes
Eric Rubin is the Editor-in-Chief of the Journal. Jane Leopold is a Deputy Editor of the Journal. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E.J. Rubin, J. Leopold, and S. Morrissey. NEJM at AHA — Intensive Blood-Pressure Control in Patients with Type 2 Diabetes. N Engl J Med. DOI: 10.1056/NEJMe2414476.
Nov 15, 2024 • 4min
NEJM at AHA — Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
Eric Rubin is the Editor-in-Chief of the Journal. Jane Leopold is a Deputy Editor of the Journal. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E.J. Rubin, J. Leopold, and S. Morrissey. NEJM at AHA — Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. DOI: 10.1056/NEJMe2414470.
Nov 15, 2024 • 4min
NEJM at AHA — Left Atrial Appendage Closure after Ablation for Atrial Fibrillation
Eric Rubin is the Editor-in-Chief of the Journal. Jane Leopold is a Deputy Editor of the Journal. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E.J. Rubin, J. Leopold, and S. Morrissey. NEJM at AHA — Left Atrial Appendage Closure after Ablation for Atrial Fibrillation. N Engl J Med. DOI: 10.1056/NEJMe2414475.
Nov 15, 2024 • 4min
NEJM at AHA — CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy
Eric Rubin is the Editor-in-Chief of the Journal. Jane Leopold is a Deputy Editor of the Journal. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E.J. Rubin, J. Leopold, and S. Morrissey. NEJM at AHA — CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy. N Engl J Med. DOI: 10.1056/NEJMe2414473.
